Lutetium Lu-177 vipivotide tetraxetanPSMA-targeted radioligand
Lutetium Lu-177 vipivotide tetraxetan combines a PSMA-targeting molecule with a radioactive isotope. Its clinical purpose is selected advanced prostate-cancer treatment, not supplementation or general peptide therapy.
What is Lutetium Lu-177 vipivotide tetraxetan?
Lutetium-177 vipivotide tetraxetan is a PSMA-targeted radioligand treatment for defined advanced prostate-cancer settings. It is a targeted radioactive medicine, not a nutritional peptide. 1 2
How it works
The targeting component binds prostate-specific membrane antigen (PSMA), delivering lutetium-177 radiation to PSMA-expressing tissue. Imaging and clinical selection help identify appropriate patients. 2
Effects studied
Advanced prostate-cancer outcomes
VISION assessed survival and radiographic progression in previously treated, PSMA-positive metastatic castration-resistant prostate cancer. The trial population should remain attached to the result.
Evidence: Randomised clinical trial. 1
What does the evidence show?
Randomised advanced-prostate-cancer radioligand trial
The active effect includes radiation
The targeting component binds prostate-specific membrane antigen, or PSMA, which can be abundant on prostate-cancer cells. Attached lutetium-177 emits radiation that damages the tissues taking it up. The treatment therefore delivers a cytotoxic effect rather than simply changing a receptor signal.
Why a scan is part of the selection
PSMA expression varies. Imaging helps identify people whose disease is suitable for a PSMA-targeted approach, and not every metastasis necessarily behaves the same way. The biology shown on a scan, previous treatments and organ function all affect whether trial findings fit an individual situation.
What the major study established
The retained VISION trial examined a selected, previously treated population with metastatic castration-resistant prostate cancer. It evaluated survival and radiographic progression alongside standard care. Those results are meaningful, but they cannot be extended automatically to earlier disease, PSMA-negative cancer or a different treatment sequence. 1
Targeting does not eliminate toxicity
Bone-marrow suppression, kidney effects and other adverse reactions remain concerns, and treatment requires radiation precautions. Product indications have evolved, so the current local label must be checked for the precise treatment setting. The trial described here does not establish which historical or new indications apply in Europe or Switzerland. 2 3
Safety & status
Bone-marrow and kidney effects require monitoring. Radiation precautions and product-specific selection criteria are integral to treatment. 2 3
Country and product status
Product indications and availability vary by country; current EU and Swiss status has not been independently checked for this draft.
Frequently asked questions
Is any prostate-cancer diagnosis enough to qualify?
No. PSMA expression, disease state, prior treatment and the current product indication all matter. 1 2
Is this the same treatment as lutetium-177 DOTATATE?
No. They share a radioactive isotope but target different receptors and different cancer settings.
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- Retained paper reference Archive research lead · Retained archive reference; not independently checked for this draft
- Retained source reference Archive research lead · Retained archive reference; not independently checked for this draft
- Retained source reference Archive research lead · Retained archive reference; not independently checked for this draft
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.